Tanvex Presents Results of TX05 (biosimilar- trastuzumab) in P-III Study for the Treatment of HER2-Positive Early Stage Breast Cancer at ESMO 2021
Shots:
- The P-III study evaluates TX05 (biosimilar- trastuzumab) vs Herceptin in 809 patients with HER2-positive early-stage breast cancer
- The results showed that the proportions of patients that meet pCR criteria for equivalence were highly similar b/w TX05 (48.8%) and TRA (45.3%) cohorts; ORR (84.3%) & (85.0%); CR; PR and stable disease were also highly similar- patients experienced TEAEs (62.4% vs 62.5%)- respectively
- Additionally- the therapy was well tolerated & the safety profile was consistent with the known profile of TRA
| Ref: Centre for Biosimilar | Image: Tanvex Biopharma
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com